Liver Cancer SUMMIT 2021


5-6 February 2021 Virtual Conference
N. Poster
Poster title
Applicant name
  P-001 Surgery versus Sorafenib in case of BCLC-C hepatocellular carcinoma: an Italian weighted study Simone Famularo Received Received
  P-002 Current Trends of Hepatocellular Carcinoma Characteristics in Greece Georgios Markakis Received Received
  P-003 Patterns of response to atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) from the Phase 1b GO30140 study Stacey Stein Received Received
  P-004 Association between serum magnesium concentration and hepatocellular carcinoma in cirrhotic patients Simona Parisse Received Received
  P-005 The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database Francesca Carissimi Received Received
  P-006 Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids Mikel Ruiz de Gauna Received Received
  P-008 Study on Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy Haochen Wang Received Received
  P-009 Hepatocellular carcinoma prognostic scores: filling the gap? Michele Campigotto Received Received
  P-010 A real-world evaluation of baseline characteristics, treatment patterns, and survival outcomes in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein levels receiving second-line therapy in the United States Rajiv Ulpe Received Received
  P-011 Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target? Alberto Zanetto Received Received
  P-012 Comparison of Sorafenib and Lenvatinib as first line therapy in Unresectable Hepatocarcinoma: a multi-center propensity score matching analysis Margherita Rimini Received Received
  P-013 chronic hepatitis b under tenofovir or entecavir: performance of the page-b score to predict hepatocellular carcinoma Daniela Falcão Received Received
  P-014 Diagnosing hepatocellular carcinoma are we getting it right first time? Emma Saunsbury Received Received
  P-015 Modeling hepatocellular carcinoma cells dynamics by serological and imaging biomarkers in patients with response to sorafenib and/or regorafenib Piero Colombatto Received Received
  P-016 Profiling of cell-free DNA using Whole-exome sequencing in patients with Hepatocellular carcinoma in Thailand Pattapon Kunadirek Received Received
  P-017 Transcriptomic analyses reveal cancer-induce genes in PBMCs of Hepatocellular carcinoma for early diagnosis and prognosis Pattapon Kunadirek Received Received
  P-018 Association between postoperative early recurrence of hepatocellular carcinoma and the expression pattern of circulating tumor cells in peripheral blood sample: a preliminary study. Cristina Ciulli Received Received
  P-019 Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma Filippo Pelizzaro Received Received
  P-020 Establishment of 3D-organoids from cryopreserved cancer tissues Colin Rae Received Received
  P-021 Prognostic role of platelets-to lymphocytes ratio (PLR) and neutrophils-to-lymphocytes ratio (NLR) in hepatocellular carcinoma patients Filippo Pelizzaro Received Received
  P-022 Impact of hospital volume on hepatocellular carcinoma survival in Italy Filippo Pelizzaro Received Received
  P-023 Sarcomatoid hepatocellular carcinoma has distinct immunologic hallmarks from ordinary hepatocellular carcinoma Ryo Morisue Received Received
  P-024 Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study OPEN Health Received Received
  P-025 Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2cm or smaller: a cohort study in Taiwan Ching-Sheng Hsu Received Received
  P-026 Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma OPEN Health Received Received
  P-027 Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. Petros Fessas Received Received
  P-028 Are undetected stones in the common biliary duct one of the causes of abscesses and bilomas development after percutaneous thermal ablation procedures? Letizia Veronese Received Received
  P-029 Different modalities in management of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients with or without hepatocellular Carcinoma Mohamed Abdel-Samiee Received Received
  P-030 Copper chelators old drugs for new uses in the treatment of hepatocellular carcinoma Silvano Junior Santini Received Received
  P-031 Diagnostic accuracy of a-fetoprotein (AFP), protein induced by vitamin K absence (PIVKA-II) and fibrogen like protein-2 (FGL-2) for HCC diagnosis among patients with liver cirrhosis antonia syriha Received Received
  P-032 NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice MACARENA HERRANZ ITÚRBIDE Received Received
  P-033 Development of ex vivo and in vivo tissue models of hepatocellular carcinoma and utility for immunotherapy investigations Amy Collins Received Received
  P-034 Methylated Septin 9 (mSEPT9) as a biomarker for hepatocellular carcinoma. Results from University Hospital Coventry and Warwickshire NHS Trust, UK Ayman Bannaga Received Received
  P-036 Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. David Pinato Received Received
  P-037 PNPLA3 and Notch3 gene polymorphisms as risk factors for alcoholic cirrhosis development and its progression to hepatocellular carcinoma Anna Mrzljak Received Received
  P-038 Urinary volatile organic compounds characterization in hepatocellular carcinoma pilot study Ayman Bannaga Received Received
  P-039 Comparison of incidence and mortality risks due to acute kidney injury in hepatocellular carcinoma patients after liver resection, ablation, and transarterial chemoembolization: Meta-analysis of cohort studies Boby Pratama Putra Received Received
  P-040 Predictive value of biomarkers a-fetoprotein (AFP) and fibrogen like protein-2 (FGL-2) for HCC among patients with liver cirrhosis antonia syriha Received Received
  P-041 Transarterial chemoembolization: Predictors of liver function deterioration prior to hepatocellular carcinoma refractoriness Joel Ferreira-Silva Received Received
  P-042 Two birds one stone: a case of synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma Catarina Félix Received Received
  P-043 Virtual biopsy for diagnosis of steatohepatitis and chemotherapy-associated liver injuries. A combined radiomic and clinical model. Guido Costa Received Received
  P-045 Hepatic and extrahepatic colorectal metastases have discordant responses to systemic therapy. Pathology data from patients undergoing simultaneous resection of multiple tumor sites Pio Corleone Received Received
  P-046 A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. Thomas Talbot Received Received
  P-047 Hsa-miR-21-5p disturbs the liver metabolic network in patients with NAFLD and is increased in NASH-associated HCC, contributing to hepatocarcinogenesis in mice Pedro Rodrigues Received Received
  P-048 Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC. A single center retrospective case control study. Bianca Rocco Received Received
  P-049 Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash-out Lorenzo Mulazzani Received Received
  P-050 Chronic disruption of the late cholesterol synthesis leads to female-prevalent liver cancer damjana rozman Received Received
  P-052 Human antigen R (HuR) SUMOylation is a fine-tuner of hepatocellular carcinoma (HCC) progression via the modulation of key mitochondrial mRNAs Sofia Lachiondo-Ortega Received Received
  P-053 GALAD Score shows improved detection of early stage hepatocellular carcinoma in a Caucasian cohort of chronic Hepatitis B and C Clemens Schotten Received Received
  P-054 Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study. Lorena Carballo-Folgoso Received Received
  P-055 Treatment of the chemotherapy induced hepatotoxicity Mariia Zharova Received Received
  P-056 Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases André L. Simão Received Received
  P-057 Hepatocellular Carcinoma Surveillance in Cirrhotic patients. Shreyashee Sengupta Received Received
  P-058 Dynamic risk profile of hepatocellular carcinoma recurrence after curative intent liver resection Tommy Ivanics Received Received
  P-059 Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma Darko Castven Received Received
  P-060 Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients Anthony Tan Received Received
  P-061 Circular RNA expression is modulated by RNA-binding proteins in hepatocellular carcinoma Rok Razpotnik Received Received
  P-062 The impact of ultrasonographic blind spots for detecting early-stage hepatocellular carcinoma during surveillance HA IL KIM Received Received
  P-063 Prognostic factors and post-treatment survival in patients enrolled onto second-line trials for unresectable hepatocellular carcinoma after sorafenib: a multicentre Italian cohort study Nicola Personeni Received Received
  P-064 FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling Giulia Cristinziano Received Received
  P-065 Phase 1 study of autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, LioCyx-M in unresectable HBV-related hepatocellular carcinoma (HCC) Regina Wong Received Received
  P-066 The combination of alcohol and metabolic syndrome is a fast track to hepatic tumorigenesis Raquel Benedé-Ubieto Received Received
  P-067 Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study Linda Skibsted Kornerup Received Received
  P-068 Usefulness of circulating tumor cells in the management of patients with hepatocellular carcinoma Elena Vargas Accarino Received Received
  P-069 Prognostic value of metabolic imaging data of C-choline PET/CT in patients undergoing hepatectomy for hepatocellular carcinoma Jacopo Galvanin Received Received
  P-070 First real-life experience with atezolizumab plus bevacizumab in the treatment of advanced hepatocellular carcinoma Martin Schnlein Received Received
  P-071 Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells Alessandra Gentilini Received Received
  P-072 Alteration of miRNA content in extracellular vesicles in Sorafenib-treated liver cancer cells. miRNA prognostic value in plasma from patients with advanced HCC treated with Sorafenib Patricia de la Cruz-Ojeda Received Received
  P-073 Virological and oncological factors of HCC recurrence after liver trasplantation in a single transplant center Martina Gambato Received Received
  P-074 Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma Claudia Campani Received Received
  P-075 Tumor Burden Score: a novel tool to predict immune-related liver injury during immunotherapy for hepatocellular carcinoma Antonio DAlessio Received Received
  P-076 Phase 3 KEYNOTE-937 Trial: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response After Surgical Resection or Local Ablation Arndt Vogel Received Received
  P-077 PRPF8 regulates FAK/AKT pathway via fibronectin 1 splicing modulation to promote hepatocellular carcinoma aggressiveness Juan Luis López-Cánovas Received Received
  P-078 Retrospective analysis of one-center experience in diagnosis and treatment of liver cancer Mariia Zharova Received Received
  P-079 Analysis of risk factors associated with hepatocellular carcinoma development in patients with hepatitis B virus infection Christos Triantos Received Received
  P-081 Validation of the aMAP risk score for the development of hepatocellular cancer in patients with cirrhosis in Glasgow Chris Curran Received Received
  P-082 In vivo quantification of micro-balloon interventions (MBI) advantage. Cohort, retrospective, bi-centric study of DEB-TACE vs b-TACE and SIRT vs b-SIRT Claudio Trobiani Received Received
  P-083 Comparison of Liver Transplant Criteria for Hepatocellular Carcinoma Volkan &304;nce Received Received
  P-084 LDH as early prognostic markers for response in advanced hepatocellular carcinoma treated with Nivolumab radu Pompilia Received Received
  P-085 DNA Methyltransferases as Potential Biomarkers for Egyptian Patients with HCV Related Hepatocellular Carcinoma Mohamed Abdel-Samiee Received Received
  P-086 Survival analysis of the most frequent Single Nucleotide Variants in Hepatocellular Carcinoma Jimmy A. Daza Barragan Received Received
  P-087 Se and Zn supplements attenuates HCC among recovered Hepatitis C Obese population in Middle Belt Nigeria. OLAJUYIN OLALEYE Received Received
  P-088 CAMD score predicts the risk of hepatocellular carcinoma in Tunisian patients with chronic hepatitis B on antiviral therapy Myriam Ayari Received Received
  P-089 Centrality of Estrogen Receptor 1 in Modulating Hepatocellular Carcinoma Progression through Wnt signaling Elisa Pasini Received Received
  P-090 Hepatoprotective effects of pirfenidone in early stages of hepatocellular carcinoma Jorge Silva-Gomez Received Received
  P-091 Real-world experience of hepatocellular carcinoma patients after sorafenib treatment: eligibility to subsequent lines and prognostic factors. Leonardo Gomes da Fonseca Received Received
  P-092 Hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors Nicola Personeni Received Received
  P-093 Identification of a prognostic 3-protein score of childhood liver cancer by proteomic profiling Juan Carrillo Received Received
  P-094 Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome. Maria Guarino Received Received
  P-095 Title: Quantification of extracellular matrix features and its implications in hepatocellular carcinoma patients after curative liver resection Kaiwen Huang Received Received
  P-096 Enhanced mitochondrial activity and immunometabolic reprogramming, by silencing Methylation Controlled J protein (MCJ), accelerates liver tumorigenesis in a hepatocellular carcinoma (HCC) mice model Naroa Goikoetxea-Usandizaga Received Received
  P-097 Absence of a complete response after two trans-arterial chemo-embolizations during liver transplantation waiting list: should we persist or change? Edoardo Poli Received Received
  P-098 Prediction of early recurrence of hepatocellular carcinoma after resection: international validation of the ERASL risk models Berend Beumer Received Received
  P-099 Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment Thorben Frndt Received Received
  P-100 PD-1 expression, polymorphisms in PDCD1 and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). HELEN REEVES Received Received
  P-101 Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma? Ciro Celsa Received Received
  P-102 Circulating miR 373 but not miR 210 as a new promising preoperative predictor of response to superive transarterial chemoembolization bridging therapy in Egyptian patients with hepatocellular carcinoma on top of hepatitis C virus infection Omneya AbdelKarem Received Received
  P-103 Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients Berend Beumer Received Received
  P-105 Endothelial Angiopoietin-2 overexpression in explanted HCCs identifies subjects at high risk of recurrence after liver transplant Alessandra Pivetti Received Received
  P-106 Role of LI-RADS indeterminate observations in the prediction of HCC occurrence after direct antiviral therapy for hepatitis C virus infection. Francesco Matteini Received Received
  P-107 lncRNA-H19 as a marker of liver disease progression: Hepatocellular Carcinoma Ángela Rojas Received Received
  P-108 Nanobody-targeted liposomes for photodynamic therapy of Cholangiocarcinoma Bárbara Mesquita Received Received
  P-109 Effectiveness of hepatocellular carcinoma treatments with curative intent: a nationwide study Frederik Kraglund Received Received
  P-110 Epidemiological trends of hepatocellular carcinoma in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD) in Italy. Monica Cucco Received Received
  P-111 An unexpected side effect of lenvatinib in patients treated for advanced hepatocellular carcinoma: increased hemoglobin level and erythrocytosis Alina Pascale Received Received
  P-112 Are Radiology-based endpoints robust surrogate outcomes of overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization? Ciro Celsa Received Received
  P-113 Vimentin expression in hepatocellular carcinoma relates with progenitor cells and epithelial-mesenchymal transition carcinogenesis Joana Espírito Santo Received Received
  P-114 Inducing tissue-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma Nekisa Zakeri Received Received
  P-115 Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment Gemma Iserte Received Received
  P-117 Cancer-associated pathways modulated by O-GlcNAc transferase and Enhancer of Zeste homolog 2 in hepatocellular carcinoma Massimo Levrero Received Received
  P-118 Assessment of the impact of COVID-19 pandemic on Liver Cancer Management (CERO-19) Sergio Munoz-Martínez Received Received
  P-119 Modified Page B Score Performance in Predicting HCC Risk in patients with chronic hepatitis B on antiviral therapy. Fatma Ben Farhat Received Received
  P-121 Liver decompensation as late complication in HCC patients with long term response following ive internal radiation therapy. Diederick van Doorn Received Received
  P-122 Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma Nouha Trad Received Received
  P-123 Safety and benefit of the combination of regorafenib and nivolumab in patients with hepatocellular carcinoma (HCC) in progression beyond two lines of oral chemotherapy Ben merabet Yasmina Received Received
  P-124 Incidence of Hepatocellular Carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A Systematic Review Meta-Analysis and Meta-Regression Marco Sanduzzi Zamparelli Received Received
  P-125 Performance of ten non-invasive liver function tests in predicting one-year mortality in patients with hepatocellular carcinoma Nouha Trad Received Received
  P-126 Impact of Hepatocellular Carcinoma screening in patients with Non-Achoholic Fatty Liver Disease and survival analyzis: a Brazilian Cross-Section Study Regiane Saraiva de Souza Melo Alencar Received Received
  P-127 Whole-transcriptome profiling of biopsies from unresectable intrahepatic cholangiocarcinoma (iCCA) reveals a prognostic signature with treatment implications. Massimiliano Salati Received Received
  P-128 Complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or waiting and see strategy? Alessandro Vitale Received Received
  P-129 PSMA PET/CT imaging has equivalent performance to MRI for characterising hepatocellular carcinoma Veronica Wong Received Received
  P-130 Stellate cell activation in liver cancer treatment Xiaowen Liang Received Received
  P-131 Efficacy and safety of pemigatinib in European patients with previously treated locally advanced or metastatic cholangiocarcinoma: a FIGHT-202 subgroup analysis Antoine Hollebecque Received Received
Tel.: +34 91 736 2385
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name


Liver Cancer SUMMIT 2021


5-6 February 2021 Virtual Conference

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 11/01/2021 TO 05/02/2022
Featured Poster
Vote poster
Poster Discussion

Logo Draft
Logo Cert